ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment options"

  • Abstract Number: 2512 • 2018 ACR/ARHP Annual Meeting

    Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar

    Lisa Baganz1, Yvette Meißner1, Perter Herzer2, Jürgen Braun3, Anett Gräßler4, Anja Strangfeld5 and Angela Zink6, 1Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, 2Scientific Advisory Board, Munich, Germany, 3Ruhr-University Bochum, Bochum, Germany, 4Rheumatologist, Pirna, Germany, 5Epidemiology, German Rheumatism Research Center, Berlin, Germany, 6Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany

    Background/Purpose: The number of biosimilars approved for the treatment of rheumatoid arthritis (RA) is constantly increasing. Until now, there are just a few analyses investigating…
  • Abstract Number: 972 • 2017 ACR/ARHP Annual Meeting

    JAK/STAT Mediated Inhibition of Mir-23a~24-2~27a Cluster Potentiates Activation of CD14+ Monocytes in Treatment-Resistant RA

    Marina Frleta-Gilchrist, Donna McIntyre, Aziza Elmesmari, Lynn Stewart, Derek Baxter, Mariola Kurowska-Stolarska, Derek Gilchrist and Iain B. McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: While emerging and existing treatments of RA allow better options and clinical outcomes for patients, studies informing drug resistant states and further clinical therapeutic…
  • Abstract Number: 1430 • 2017 ACR/ARHP Annual Meeting

    Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?

    Lisa Baganz1, Adrian Richter1, Yvette Meißner2, Matthias Schneider3, Anke Liebhaber4, Ilka Schwarze5, Anja Strangfeld6 and Angela Zink7, 1German Rheumatism Research Center, Berlin, Germany, 2Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, 3Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, 4Rheumatologist, Halle, Germany, Halle, Germany, 5Rheumatologist, Leipzig, Germany, Leipzig, Germany, 6Epidemiology, German Rheumatism Research Center, Berlin, Germany, 7German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany

    Background/Purpose: A recent US-study suggests considerable underuse of MTX and too early switches to biologic (b)DMARDs1  before using a high MTX dose or changing the…
  • Abstract Number: 597 • 2016 ACR/ARHP Annual Meeting

    Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015

    Thomas Frisell1, Mats Dehlin2, Daniela Di Giuseppe3, Nils Feltelius4, Alf Kastbom5, Carl Turesson6, Johan Askling7 and the ARTIS Study Group, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Clinical Epidemiology Unit, Dept. of Medicine, K2, Karolinska institutet, Stockholm, Sweden, 4Swedish Medical Products Agency, Uppsala, Sweden, 5Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, 6Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, 7Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose:  Although evidence from randomized trials suggest similar efficacy and safety on a group level for the different anti-TNF drugs available for the treatment of…
  • Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting

    Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients

    Branca Souza1, Juliana Valim2, Fernanda Chaer3, Fernanda Guimarães4 and Verônica Lima5, 1Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, 2Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, 3Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, 4Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, 5Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil

    Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
  • Abstract Number: 2238 • 2016 ACR/ARHP Annual Meeting

    RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community

    Baojin Zhu1, Lawrence Chang1, Leilei Qian1, Cynthia J Larmore1, Yoko Tanaka2 and Andre B. Araujo1, 1Eli Lilly and Company, Indianapolis, IN, 2Eli Lilly and Company, Indianapolis, KS

    Background/Purpose: Medications used to manage RA vary in efficacy, safety, and convenience of use. A better understanding of patient preferences of these attributes is key…
  • Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting

    Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study

    Francesca Ometto1, Bernd Raffeiner2,3, Costantino Botsios2, Davide Astorri4, Lara Friso2, Livio Bernardi5, Leonardo Punzi6 and Andrea Doria2, 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, 2Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, 3Rheumatology Unit, Internal Medicine, General Hospital of Bolzano, Bolzano, Italy, 4Rheumatology Unit, Department of Medicine - DIMED, University of Padova, padova, Italy, 5Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, 6Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy

    Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…
  • Abstract Number: 138 • 2015 ACR/ARHP Annual Meeting

    Identification and Documentation of Secondary Osteoarthritis in Patients with Primary Inflammatory Arthritides Using a Patient MDHAQ/RAPID3 and a Physician Estimate of Joint Damage to Recognize Patient Complexity and Inform Management Decisions

    Kathryn A. Gibson1, Annie Huang2, Katherine J. Bryant3 and Theodore Pincus2, 1Liverpool Hospital, Liverpool, Australia, 2Rheumatology, Rush University Medical Center, Chicago, IL, 3University of New South Wales, Sydney, Australia

    Background/Purpose: Patients with inflammatory arthritides may have secondary osteoarthritis (OA), which affects decisions concerning clinical management. For example, in one study, about 20% of patients…
  • Abstract Number: 144 • 2015 ACR/ARHP Annual Meeting

    One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis

    Tao Gu1, Derek Tang2, Gaurav Deshpande1, Debra F Eisenberg1 and David J. Harrison3, 1HealthCore, Wilmington, DE, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Switching a biologic treatment or escalating biologic doses are common approaches used upon biologic treatment failure. The objective of this study was to estimate…
  • Abstract Number: 601 • 2015 ACR/ARHP Annual Meeting

    Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis

    Antoine Vanier1, Florence Tubach2, Toni Alfaiate3, Xavier Mariette4 and Bruno Fautrel5, 1Biostatistics, Public Health and Medical Informatics, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6, Paris, France, 2Epidemiology and Clinical Research, AP-HP Bichat Hospital / University of Paris-Diderot / INSERM CIC-EC 1425, Paris, France, 3Epidemiology and Clinical Research, AP-HP Bichat Hospital / INSERM CIC-EC 1425, Paris, France, 4Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 5Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France

    Background/Purpose: Once remission is achieved for patients with rheumatoid arthritis (RA), treatment down-titration should be attempted, for safety issues or economic reasons. One of the…
  • Abstract Number: 2541 • 2015 ACR/ARHP Annual Meeting

    Improving Adherence with Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the Traction Trial

    Daniel H. Solomon1, Sara Lee2, Agnes Zak2, Jen Agosti3, Asaf Bitton4, Liana Fraenkel5, Leslie Harrold6, Elena Losina7, Bing Lu8, Theodore Pincus9, Josef S. Smolen10 and Jeffrey N. Katz11, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3JRA Consulting, Andover, MA, 4Medicine, Brigham and Women's Hospital, Boston, MA, 5Medicine, Yale University School of Medicine, New Haven, CT, 6Dept of Medicine, UMass Medical School, Worcester, MA, 7Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA, 8Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, 9Medicine-Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 10Medical University of Vienna, Vienna, Austria, 11Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose:   Treat to target (TTT) is a recommended paradigm in the management of rheumatoid arthritis (RA).  However, various data sources suggest that TTT is…
  • Abstract Number: 2484 • 2014 ACR/ARHP Annual Meeting

    Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working-Aged Early Rheumatoid Arthritis Patients

    Vappu Rantalaiho1, Kari Puolakka2, Janne Martikainen3, Hannu Kautiainen4,5,6 and Marjatta Leirisalo-Repo7,8, 1Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, 2Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 3Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, 4Department of General Practice, University of Helsinki, Helsinki, Finland, 5Unit of Primary Health Care, Turku University Hospital, Turku, Finland, 6Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 7Department of Clinical Medicine, University of Helsinki, Helsinki, Finland, 8Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland

    Background/Purpose To study the cost-effectiveness of adding initial infliximab to a remission-targeted combination treatment with disease modifying antirheumatic drugs (DMARDs) in early rheumatoid arthritis (RA).…
  • Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of Iguratimod for Rheumatoid Arthritis

    Tsuneo Kondo1, Akiko Shibata1, Ryota Sakai1, Kentaro Chino1, Ayumi Okuyama1, Hirofumi Takei1 and Koichi Amano2, 1Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 2Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
  • Abstract Number: 94 • 2014 ACR/ARHP Annual Meeting

    Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA

    Marcia Genta, Dallas Arthritis Center, Dallas, TX

    Background/Purpose: Biologics, a relatively new widely used class of medication that can substantially improve the course of RA, are expensive and their use is not…
  • Abstract Number: 2502 • 2014 ACR/ARHP Annual Meeting

    Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis

    I.M. Markusse1, G. Akdemir2, L. Dirven2, M. van den Broek2, K.H. Han3, H.K Ronday4, P.J.S.M. Kerstens5, W.F. Lems6,7, T.W.J. Huizinga2 and C.F. Allaart2, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, MCRZ hospital, Rotterdam, Netherlands, 4Rheumatology, Haga Hospital, The Hague, Netherlands, 5Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 6Rheumatology, VU Medical Center, Amsterdam, Netherlands, 7Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    Background/Purpose: To determine the optimal treatment strategy in patients with anti-citrullinated protein antibodies (ACPA) negative (‒) rheumatoid arthritis (RA), as it has been suggested that…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology